SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is experiencing significant volatility and community debate after pulling its compounded GLP-1 drug amid a patent infringement lawsuit from Novo Nordisk and increased regulatory scrutiny. Investors are sharply divided between calls for a short squeeze and a rebound from oversold levels, and predictions of further downside due to ongoing legal and business model challenges.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies ($PGY) is trending due to a significant market sell-off following its Q4 earnings, where conservative guidance for the coming year overshadowed stronger-than-expected profitability. The community is debating whether this reflects an extreme overreaction to management's focus on prudent risk management or a deeper concern within the AI-powered fintech sector.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is trending due to its all-stock acquisition of Valaris (VAL), a strategic consolidation that the community largely views as enhancing its market leadership and pricing power in an anticipated offshore drilling upcycle, though some express concerns over share dilution.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings is currently trending after its stock dramatically dropped following news of an SEC review into its accounting practices, reduced guidance, and the departure of its CFO and General Counsel. The community is sharply divided, with some calling it an extreme "overreaction" and a unique "buy-the-dip" opportunity, while others express severe concerns about potential financial improprieties, urging investors to "stay away" until more clarity emerges.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is trending as the community discusses its strategic acquisition of StereoLabs, which creates a unified lidar and camera platform for Physical AI applications. This move is largely seen as strengthening Ouster's market leadership and accelerating its path to profitability through StereoLabs' EBITDA-positive business.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is experiencing a sharp sell-off after issuing a weaker-than-expected revenue outlook and withdrawing its long-term targets, intensifying broader market fears about AI disruption to the traditional software sector. Despite beating Q4 earnings, the community is divided between those viewing the steep decline as an overreaction and a buying opportunity, and others who believe AI poses a fundamental threat to the SaaS business model.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

ELF Beauty is trending amidst a surprising stock drop following strong earnings and raised guidance, prompting community debate on whether a recent advertisement or market overreaction is to blame for the 'senseless dip' that many investors are seizing as a buying opportunity.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics is trending as its Eversense 365 one-year implantable CGM recently received European CE Mark approval and integrated with the twiist automated insulin delivery system, signaling potential for expanded market access. While the community highlights the product's superior technology and opportunities from competitor issues, many investors express mixed sentiment due to concerns over management's commercial execution and historical stock performance.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

REGENXBIO is trending due to intense community speculation surrounding an imminent FDA decision on its RGX-121 gene therapy for Hunter Syndrome, as a recent clinical hold on the program and a related therapy, stemming from a serious adverse event, has many anticipating a Complete Response Letter or a regulatory delay.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as the community eagerly discusses the recently inaugurated Eagle Line pilot production facility, seen as a pivotal move towards scalable solid-state battery manufacturing and potential new OEM partnerships. Many anticipate its upcoming earnings report will provide crucial commercialization details, potentially fueling a significant market re-rate from current levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Conduit Pharmaceuticals Inc. (CDT) tumbled 17% on Wednesday after the company announced that it has entered into a development agreement with privately held animal health company Manoira Corporation.As part of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://s3.amazonaws.com/b2icontent.irpass.cc/2892/rl146071.pdf">agreement</a>, Manoira will evaluate Conduit's clinical-stage candidates AZD1656 and AZD5658 in animal health indications.Manoira will initially focus on the evaluation of AZD1656 in animal Osteoarthritis. Osteoarthritis is a degenerative joint condition in companion animals.The collaboration will help Conduit accelerate its understanding of AZD1656's mechanism of action, safety profile, and potential efficacy across species, while retaining ownership of all data and intellectual property generated for human applications.The partnership, Conduit said, opens potential new revenue streams in the high-growth veterinary market.The parties will determine any future financial benefits and implications upon review of the results of the evaluations and how to proceed as a result of any such findings, Conduit said.Manoira has agreed to fund all the developmental activities of the collaboration, and Conduit has agreed to issue Manoira an up-front consideration of $500,000. Conduit’s consideration will be settled through the issuance of 154,799 shares of common stock at $3.23, or its closing price on Tuesday.On Stocktwits, retail sentiment around CDT stayed unmoved within the ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1264/128;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_04_at_11_58_35_AM_png_7bfe8d0833.webp" alt="CDT's Sentiment Meter and Message Volume as of 12:00 p.m. ET on June 4, 2025 | Source: Stocktwits" width="1264" height="128"><figcaption>CDT's Sentiment Meter and Message Volume as of 12:00 p.m. ET on June 4, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they bought the stock during the dip.<stembedurl>https://stocktwits.com/BankingBig/message/616778690</stembedurl>Another sees it rising back to over $10.<stembedurl>https://stocktwits.com/LetsgoDudeszi/message/616768852</stembedurl><a href="https://stocktwits.com/symbol/CDT">CDT stock</a> is down by approximately 98% this year and has lost most of its value over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/lucid-inks-deal-with-graphiteone/chkuKwsRbwU">Lucid Inks Deal With Graphite One To Strengthen Local Graphite Supply Chain: Retail Sees Stock Hitting $3 To $5 In Coming Months</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Conduit Pharmaceuticals Enters Development Agreement With Manoira To Test Drugs In Animals: Retail Sees Stock Above $10

Manoira will initially focus on the evaluation of AZD1656 in animal Osteoarthritis.

Equity

Shares of Conduit Pharmaceuticals Inc. (CDT) dropped 5% on Friday morning after the company’s board <a target="_blank" rel="noopener noreferrer nofollow" href="https://s3.amazonaws.com/b2icontent.irpass.cc/2892/rl145666.pdf">approved</a> a 1-for-15 reverse stock split of its common stock.Earlier, shareholders approved the stock split proposal in a meeting on May 5, leaving it upon the board to determine the exact split ratio.The company said the reverse stock split will become effective on May 19 at 5:00 p.m. ET, and the stock will start trading on a reverse stock-split adjusted basis at market open on May 20.On May 19 evening, every 15 shares of the firm’s issued and outstanding common stock will be combined into one share, reducing the number of outstanding shares of common stock to about 755,900.The company said no fractional shares will be issued in connection with the split, and those entitled to a fractional share will instead receive a proportional cash payment.Earlier this month, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://s3.amazonaws.com/sec.irpass.cc/2892/0001641172-25-010405.htm">flagged</a> doubts regarding its ability to continue as a going concern for at least the next 12 months.It said management has determined it does not have sufficient cash and other sources of liquidity to fund its current business plan, adding that it had cash and cash equivalents of only $2.1 million as of the end of the first quarter.On Stocktwits, retail sentiment around Conduit Pharmaceuticals remained unmoved within the ‘bearish’ territory over the past 24 hours while message volume remained at ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_16_at_10_29_21_AM_png_0ccaac1374.webp" alt="CDT's Sentiment Meter and Message Volume as of 10:30 a.m. ET on May 16, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>CDT's Sentiment Meter and Message Volume as of 10:30 a.m. ET on May 16, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user, however, expressed skepticism about the stock’s performance.<stembedurl>https://stocktwits.com/rkfrkf/message/614872963</stembedurl>The shares closed at over $1 last in early April.<a href="https://stocktwits.com/symbol/CDT">CDT stock</a> is down 95% this year and has lost nearly all of its value over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/trump-says-tariff-deals-with-other-countries-in-two-three-weeks/chiwIazRbnt">Trump Says Tariff Deals With Other Nations To Be Set Within 2 To 3 Weeks: ‘I Think We’re Going To Be Very Fair’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Conduit Pharma Stock Drops On Reverse Stock Split Announcement: Retail’s Pessimistic

The company said that the reverse stock split will become effective on May 19 at 5:00 p.m. ET, and the stock will start trading on a reverse stock-split adjusted basis at market open on May 20. 

Conduit Pharma Stock Drops On Reverse Stock Split Announcement: Retail’s Pessimistic 

The company said that the reverse stock split will become effective on May 19 at 5:00 p.m. ET, and the stock will start trading on a reverse stock-split adjusted basis at market open on May 20. 


CDT Equity, Inc. engages in facilitating the development and commercialization of clinical assets. The company was founded by David Joszef Tapolczay and Freda C. Lewis-Hall in October 2021 is headquartered in Naples, FL.

CDT Equity Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$1.16
Prev Close	$1.12
Open	$1.17
Dividend Yield	0.00%
50-Day Moving Average	$1.50
Beta	0.80
Avg. Volume	332,440.65
PE Ratio	0.00

52-Week High	$384.00
52-Week Low	$0.911
Market Capitalization	$1.82M
EPS (Annual)	-$2,463.72
Price to Book	0.33
Revenue Per Employee	$0.00

CDT
Conduit Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CDT News

CDTConduit Pharmaceuticals Inc